Join our daily newsletter At The Bell to receive exclusive market insights
- Medical solutions company Medical Developments International (MVP) is now allowed to sell its pain relief medication, Penthrox, in Hungary
- Penthrox can be used for emergency relief of moderate to severe pain in adult patients with trauma and associated pain
- While MVP’s European decentralised procedure and national phase is now complete, the company said it is yet to achieve government reimbursement
- Once Medical Developments receives government reimbursement for Penthrox, the product will be free for patients to purchase
- This announcement follows approvals in Bosnia and Herzegovina, which were received earlier this month
- Medical Developments is up 4.1 per cent on the market today, trading for $8.13 per share
Medical solutions company Medical Developments International (MVP) is now allowed to sell its pain relief medication, Penthrox, in Hungary.
Penthrox is a fast non-opioid pain relief medication for patients with trauma and those requiring medication to relieve pain for surgical procedures.
In Hungary, Penthrox can now be used for emergency relief of moderate to severe pain in adult patients with trauma and associated pain.
Whilst MVP’s European decentralised procedure and national phase is now complete, the company said it is yet to achieve government reimbursement. However, sales can still be made to the private market.
This announcement follows approvals in Bosnia and Herzegovina, which were received earlier this month. Medical Developments says it is also currently waiting for approvals in Greece and Malta.
Medical Developments is up 4.10 per cent on the market today, trading for $8.13 per share at 1:30 pm AEST.
